RxDoctor Payments Data

Rami Apelian, MD

Neurology · Arcadia, CANPI 1255594685

Payments from drug & device makers

$479,015in general payments, 2019–2025

Across 2,317 payments — averaging $206.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$146K
  • Lundbeck LLC$49K
  • SK Life Science, Inc.$40K
  • UCB, Inc.$36K
  • Avanir Pharmaceuticals, Inc.$34K
  • Neurocrine Biosciences, Inc.$27K
  • plus $145K from 54 others

What the payments were for

  • Consulting fees$41,0649%
  • Speaking & faculty fees$372,73678%
  • Travel & lodging$18,4914%
  • Food & beverage$46,08610%
  • Education$6390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)378$145,826
Lundbeck LLC178$49,118
SK Life Science, Inc.119$40,400
UCB, Inc.181$35,678
Avanir Pharmaceuticals, Inc.85$34,442
Neurocrine Biosciences, Inc.54$27,235
Lilly USA, LLC106$24,791
Otsuka America Pharmaceutical, Inc.33$15,916
Teva Pharmaceuticals USA, Inc.131$15,439
Biohaven Pharmaceuticals, Inc.37$13,991
Sunovion Pharmaceuticals Inc.18$10,708
MDD US Operations, LLC66$10,505
Eli Lilly5$8,015
Jazz Pharmaceuticals Inc.48$6,978
Livanova USA, Inc.19$5,948
Biohaven Pharmaceutical Holding Company Ltd.29$5,819
Eisai Inc.64$5,054
Adamas Pharmaceuticals, Inc.20$4,000
Argenx US, Inc.29$1,891
AstraZeneca(2 entities)64$1,755
Acorda Therapeutics, Inc14$1,596
Amgen(2 entities)58$1,444
Pfizer55$1,172
Greenwich Biosciences, Inc.39$892
Alnylam Pharmaceuticals Inc.33$859
Amneal Pharmaceuticals LLC41$713
Novartis48$712
Ipsen Biopharmaceuticals, Inc22$583
Acadia Pharmaceuticals Inc26$564
Biogen23$515
Merz Pharmaceuticals, LLC14$442
Takeda Pharmaceuticals U.S.A., Inc.27$382
Neurelis, Inc.19$374
Sanofi16$341
EMD Serono, Inc.18$337
Axsome Therapeutics, Inc.11$303
Catalyst Pharmaceuticals, Inc.9$272
Forte Bio-pharma LLC14$228
Abbott9$217
CSL Behring9$206
Inspire Medical Systems, Inc.1$198
Grifols USA, LLC9$189
Avadel CNS Pharmaceuticals, LLC2$174
Corium, LLC5$173
Tanabe Pharma America, Inc.8$164
Arbor Pharmaceuticals, Inc.8$146
Kyowa Kirin, Inc.6$140
Impel Pharmaceuticals Inc.7$127
Zyla Life Sciences, Inc.11$123
Mallinckrodt Enterprises LLC6$115
Scilex Pharmaceuticals Inc.6$113
Sanofi-aventis U.S. LLC1$99
Medtronic(2 entities)3$99
Assertio Therapeutics, Inc.6$97
Azurity Pharmaceuticals, Inc.5$95
Mallinckrodt Hospital Products Inc.3$85
Aquestive Therapeutics, Inc.4$80
Immedica Pharma US, Inc.3$76
Impel Pharmaceuticals LLC3$76
Vertical Pharmaceuticals, LLC4$67

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$479,015 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$881,912
Medicare patients
708
Services billed
43,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5037$633,580
NuplazidPimavanserin Tartrate53$263,638
Sodium Oxybate11$210,175
RytaryCarbidopa/Levodopa82$168,703
EpidiolexCannabidiol (Cbd)25$130,446
IngrezzaValbenazine Tosylate11$89,538
AptiomEslicarbazepine Acetate14$83,952
BotoxOnabotulinumtoxina55$72,983
VyeptiEptinezumab-Jjmr13$67,922
BriviactBrivaracetam29$53,050
QuliptaAtogepant20$40,100
VimpatLacosamide16$36,557
FycompaPerampanel19$33,317
HorizantGabapentin Enacarbil11$27,768
XadagoSafinamide Mesylate16$26,794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt$1,172$657,17952 claims
Acadia Pharmaceuticals IncNuplazid$564$263,63853 claims
Amneal Pharmaceuticals LLCRytary$713$168,70382 claims
AbbVieBotox, Qulipta, Ubrelvy, Namzaric$145,826$142,537102 claims
UCB, Inc.Briviact, Vimpat$35,678$89,60745 claims
Neurocrine Biosciences, Inc.Ingrezza$27,235$89,53811 claims
Sunovion Pharmaceuticals Inc.Aptiom$10,708$83,95214 claims
Lundbeck LLCVyepti$49,118$67,92213 claims
Eisai Inc.Fycompa$5,054$33,31719 claims
Arbor Pharmaceuticals, Inc.Horizant$146$27,76811 claims
Otsuka America Pharmaceutical, Inc.Rexulti$15,916$17,31712 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$382$11,54218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in Arcadia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →